About CLINUVEL

Tuesday, 29 January 2013 19:37

JAMA features vitiligo study as cover story

In October 2012 we announced that observations from the CUV102 study of SCENESSE® (afamelanotide 16mg implant) in vitiligo were e-published in the journal Archives of Dermatology. Earlier this month the article was fully published in the re-named JAMA Dermatology, with case study images from CUV102 featured on the cover. You can access the abstract to this article at the JAMA's website.

Reference:

Grimes PE, et al (2013). "The Efficacy of Afamelanotide and Narrowband UV-B Phototherapy for Repigmentation of Vitiligo" JAMA Dermatol. 149(1):68-73.

Latest Company Announcements

09 August 2017

Form 604, 09 August 2017

Notice of change of interests of substantial holder

Read More
31 July 2017

Appendix 4C - Quarterly report

Appendix 4C

Read More
25 July 2017

CLINUVEL Newsletter - July 2017

For those who have followed the Company over the years, the journey of our teams has most often been counter-current to arrive at the present point.

Read More
10 May 2017

Appendix 3B

Appendix 3B

Read More
10 May 2017

CLINUVEL Newsletter - May 2017

I look back at a turbulent period, as CLINUVEL has brought the ‘negotiations’ with GKV-Spitzenverband (National Association of Statutory Health Insurance Funds in Germany) to a successful end.

Read More
02 May 2017

NICE ENGLAND UPDATE ON SCENESSE®

CLINUVEL announce that the Department of Health has designated SCENESSE® to be evaluated as a Highly Specialised Technology (HST)

Read More

Quick Links